JPRN-jRCT2080220332未知2 期
A Phase II multicenter trial of Gemcitabine in combination with R1415 (erlotinibhydrochloride) in patients with unresectable pancreatic cancer (locally advanced or metastatic)
适应症
试验速览
- 阶段
- 2 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Inclusion criteria
- •- Histologically or cytologically confirmed diagnosis of adenocarcinoma or adenosquamous of the pancreas cancer which is unresectable (locally advanced or metastatic).
- •- ECOG performance status (PS) of 0, 1 or 2.
- •- Adequate organ functions
- •Exclusion criteria
- •- The patient is currently suffering from such pulmonary disorders as sudden pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, active radioactive pneumonia, or drug-related pneumonia, or he/she has a history of such disease.
- •- Patients have thoracic radiotherapy.
- •- Prior treatment with Gemcitabine
- •- Patients who have had treatment with any investigational drug within 4 weeks prior to entry.
- •- Patients who have history of serious hypersensitivity reactions with any medicine.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Phase 2 single-arm studies of Gemcitabine in combination with Oxaliplatin in refractory and relapsed pediatric solid tumors - ITCC-004-GEMOXEUCTR2006-001065-41-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI156
进行中（未招募）
1 期
A multicenter, phase I-II trial of gemcitabine plus oxaliplatin and nbb-paclitaxel in subjects with advanced (unresectable or metastatic) biliary tract cancerEUCTR2016-004118-84-ITIRCCS ISTITUTO CLINICO HUMANITAS85
进行中（未招募）
1 期
A Phase 2 Single-Arm Study of Gemcitabine in Combination with Oxaliplatin in Pediatric Patients with Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS Tumors - N/AEUCTR2005-005219-36-GBEli Lilly and Company Limited70
进行中（未招募）
不适用
A Phase 2 Single-Arm Study of Gemcitabine in Combination with Oxaliplatin in Pediatric Patients with Relapsed or Refractory Neuroblastoma or Miscellaneous Solid Non-CNS TumorsEUCTR2005-005219-36-DEEli Lilly and Company Limited70
进行中（未招募）
1 期
Phase 2 single-arm studies of gemcitabine in combination with oxaliplatin in refractory and relapsed pediatric solid tumors. - ITCC-004-GEMOXRefractory or relapsing malignant pediatric solid tumors.EUCTR2006-001065-41-GBniversity Hospitals of Leicester NHS Trust, Research and Development Directorate156